Antiadhesive carbohydrates

Abstract

Provided is a pharmaceutical or dietetic product, which serves for reducing and/or blocking the adhesion of pathogenic substances and organisms to eucaryontic cells, in particular mammal cells. Said preparation contains at least one carbohydrate having an uronic acid unit on one of the ends thereof. 10 to 100% of the present, terminal uronic acid units pertaining to the carbohydrates are provided with a double bond that is especially situated between the C 4 and C 5 atom.

1 . A pharmaceutical or dietetic preparation for reducing and/or blocking the adhesion of pathogenic substances and organisms to eucaryontic cells, especially mammal cells, containing an antiadhesive carbohydrate or several antiadhesive carbohydrates having an uronic acid unit (terminal uronic acid unit) on one of the ends thereof,  
       characterized in that 
 10 to 100% of the present terminal uronic acid units of said antiadhesive carbohydrates have a double bond.  
 
     
     
         2 . The pharmaceutical or dietetic preparation of  claim 1 ,  
       characterized in that 
 10 to 100% of the antiadhesive carbohydrates having a terminal uronic acid unit comprise a reducing end, and comprise the terminal uronic acid unit on another end.  
 
     
     
         3 . The pharmaceutical or dietetic preparation of  claim 1  or  2 ,  
       characterized in that 
 50 to 100% of the double bonds are situated between the C 4  and C 5  atom of the terminal uronic acid unit.  
 
     
     
         4 . The pharmaceutical or dietetic preparation of any one of the preceding claims,  
       characterized in that 
 10 to 50% of the present terminal uronic acid units of the antiadhesive carbohydrates have a double bond.  
 
     
     
         5 . The pharmaceutical or dietetic preparation of any one of the preceding claims,  
       characterized in that 
 it contains several antiadhesive carbohydrates having a terminal uronic acid unit, which have a different degree of polymerization.  
 
     
     
         6 . The pharmaceutical or dietetic preparation of any one of the preceding claims,  
       characterized in that 
 the antiadhesive carbohydrates have a maximum degree of polymerization of DP 100, and in particular of DP 2 up to DP 40, and further in particular of DP 2 up to DP 10.  
 
     
     
         7 . The pharmaceutical or dietetic preparation of any one of the preceding claims,  
       characterized in that 
 the antiadhesive carbohydrates having a terminal uronic acid unit are obtainable starting from uronic acid-containing carbohydrates, which are chemically or enzymatically cleaved in such a manner that the indicated contents of terminal uronic acid units having a double bond are obtained.  
 
     
     
         8 . The pharmaceutical or dietetic preparation of any one of the preceding claims,  
       characterized in that 
 the content of the antiadhesive carbohydrates described in the preceding claims in neutral sugar units is a maximum of 50%, and in particular 0 to 30%.  
 
     
     
         9 . The pharmaceutical or dietetic preparation of any one of the preceding claims,  
       characterized in that 
 the degree of esterification of the antiadhesive claims described in the preceding claims with ethanol is up to 75%, and in particular 20 to 50%.  
 
     
     
         10 . The pharmaceutical or dietetic preparation of any one of the preceding claims,  
       characterized in that 
 it contains, apart from the antiadhesive carbohydrate(s), a prebiotic carbohydrate mixture of two different, essentially soluble carbohydrate components A and B, that remain undigested in the gastrointestinal tract and reach the large intestine non-absorbed,  
 that the carbohydrate component A is built up from at least one monosaccharaide or from at least one oligosaccharide (disaccharaide up to hexasaccharide) or from a mixture of two or several of these saccharides,  
 the carbohydrate component B is built up from a polysaccharide (heptasaccharide onwards) or from a mixture of two or several polysaccharides,  
 that the carbohydrate component A=5 to 95 wt-%, and the carbohydrate component B=5 to 95 wt-% of the sum of the carbohydrate components A+B (=100 wt-%), and that at least 80 wt-% of the carbohydrates/saccharides of the carbohydrate component A and B are prebiotically active, and  
 that the carbohydrates, which constitute the carbohydrate component A and the carbohydrate component B, do not represent antiadhesive carbohydrates according to  claim 1 .  
 
     
     
         11 . The pharmaceutical or dietetic preparation of  claim 10 ,  
       characterized in that 
 the weight ratio of the antiadhesive carbohydrate(s) to the prebiotic carbohydrate mixture is 1:99 up to 99:1, and in particular 1:10 up to 10:1, and furthermore in particular about 1:1.  
 
     
     
         12 . The pharmaceutical preparation of any one of the preceding claims,  
       characterized in that 
 it contains usual, pharmacologically tolerated carriers, diluents and/or other adjuvants.  
 
     
     
         13 . The dietetic preparation of any one of claims  1  through  11 ,  
       characterized in that 
 it contains usual food ingredients and food components, including vitamins and trace elements.  
 
     
     
         14 . Use of the antiadhesive carbohydrates described in any one of claims  1  through  9 , having a terminal uronic acid unit for reducing or preventing the adhesion of pathogens to eucaryontic cells.  
     
     
         15 . The use of the antiadhesive carbohydrates of  claim 14  in a quantity of at least 8 mg/kg per day, and in particular of 8 to 20 mg/kg per day.  
     
     
         16 . The use of  claim 14  or  15  for treating infections of the gastrointestinal tract, the blood system, the respiratory passages, the urogenital tract, and the nasopharyngeal meatus, and for treating damages of the cells of the gastrointestinal tract, the blood system, the respiratory passages, the urogenital tract, and the nasopharyngeal meatus caused by toxins or heavy-metal cations.